The LRIG family: Enigmatic regulators of growth factor receptor signaling

Endocrine-Related Cancer

Volumn 21, Issue 6, 2014, Pages R431-R443

  Simion, Catalina ^a   Cedano Prieto, Maria Elvira ^a   Sweeney, Colleen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Growth factor receptor; LRIG1; LRIG2; LRIG3; Stem cell; Tumor suppressor

Indexed keywords

GROWTH FACTOR RECEPTOR; LRIG1 PROTEIN, HUMAN; MEMBRANE PROTEIN;

GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MULTIGENE FAMILY; SIGNAL TRANSDUCTION;

GENE EXPRESSION REGULATION; HUMANS; MEMBRANE GLYCOPROTEINS; MULTIGENE FAMILY; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84919639057     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0179     Document Type: Review

References (81)

1. Abraira VE, Del Rio T, Tucker AF, Slonimsky J, Keirnes HL & Goodrich LV 2008 Cross-repressive interactions between Lrig3 and netrin 1 shape the architecture of the inner ear. Development 135 4091-4099. (doi:10.1242/dev.029330)
2. Abraira VE, Satoh T, Fekete DM& Goodrich LV 2010 Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3- dependent inner ear morphogenesis. PLoS ONE 5 e8981. (doi:10.1371/ journal.pone.0008981)
3. Arakawa H 2004 Netrin-1 and its receptors in tumorigenesis. Nature Reviews. Cancer 4 978-987. (doi:10.1038/nrc1504)
4. Bacchetta J & Cochat P 2010 Severe voiding dysfunction: ask the child to smile. Kidney International 78 225-226. (doi:10.1038/ki.2010.144)
5. Bai L,McEachern D, Yang CY, Lu J, Sun H & Wang S 2012 LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFa expression and receptor tyrosine kinase signaling. Cancer Research 72 1229-1238. (doi:10.1158/0008-5472.CAN-11-2428)
6. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ & Clevers H 2009 Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457 608-611. (doi:10.1038/nature07602)
7. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al. 2012 The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery 2 401-404. (doi:10.1158/2159-8290.CD-12-0095)
8. Chang L, Shi R, Yang T, Li F, LiG, Guo Y, Lang B, Yang W, ZhuangQ & Xu H 2013 Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity. Journal of Experimental & Clinical Cancer Research 32 101. (doi:10.1186/1756-9966-32-101)
9. Daly SB, Urquhart JE, Hilton E, McKenzie EA, Kammerer RA, Lewis M, Kerr B, Stuart H, Donnai D, Long DA et al. 2010 Mutations in HPSE2 cause urofacial syndrome. American Journal of Human Genetics 86 963-969. (doi:10.1016/j.ajhg.2010.05.006)
10. Del Rio T, Nishitani AM, YuWM& Goodrich LV 2013 In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear. PLoS Genetics 9 e1003824. (doi:10.1371/journal.pgen.1003824)
11. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al. 2013 Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling 6 pl1. (doi:10.1126/scisignal.2004088)
12. Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C, Zhu JX, Keene DR, Reed CC & Iozzo RV 2007 A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 26 368-381. (doi:10.1038/sj.onc.1209803)
13. Gumienny TL, Macneil L, Zimmerman CM, Wang H, Chin L, Wrana JL & Padgett RW 2010 Caenorhabditis elegans SMA-10/LRIG is a conserved transmembrane protein that enhances bone morphogenetic protein signaling. PLoS Genetics 6 e1000963. (doi:10.1371/journal.pgen. 1000963)
14. Guo D, Holmlund C, Henriksson R & Hedman H 2004 The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 84 157-165. (doi:10.1016/j.ygeno.2004.01.013)
15. Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H & Henriksson R 2006 Perinuclear leucine-rich repeats and immunoglobulin- like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathologica 111 238-246. (doi:10.1007/s00401-006-0032-5)
16. Gur G, Rubin C, KatzM, Amit I,Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H et al. 2004 LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO Journal 23 3270-3281. (doi:10.1038/sj.emboj.7600342)
17. Hanlon K, Rudin CE & Harries LW 2009 Investigating the targets of MIR- 15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). PLoS ONE 4 e7169. (doi:10.1371/journal.pone.0007169)
18. Hedman H & Henriksson R 2007 LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? European Journal of Cancer 43 676-682. (doi:10.1016/j.ejca.2006.10.021)
19. Hedman H, Nilsson J, Guo D & Henriksson R 2002 Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncologica 41 352-354. (doi:10.1080/028418602760169398)
20. Hedman H, Lindstrom AK, Tot T, Stendahl U, Henriksson R & Hellberg D 2010 LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncologica 49 812-815. (doi:10.3109/0284186X.2010.492789)
21. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R & Hedman H 2004 Characterization and tissue-specific expression of human LRIG2. Gene 332 35-43. (doi:10.1016/j.gene.2004.02.002)
22. Holmlund C, Haapasalo H, Yi W, Raheem O, Brannstrom T, Bragge H, Henriksson R & Hedman H 2009 Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology 29 242-247. (doi:10.1111/j.1440-1789.2008.00970.x)
23. Hong B, van den Heuvel AP, Prabhu VV, Zhang S & El-Deiry WS 2014 Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Current Drug Targets 15 80-89. (doi:10.2174/1389450114666140106101412)
24. Jensen KB & Watt FM 2006 Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence. PNAS 103 11958-11963. (doi:10.1073/pnas.0601886103)
25. Jensen KB, Jones J & Watt FM 2008 A stem cell gene expression profile of human squamous cell carcinomas. Cancer Letters 272 23-31. (doi:10.1016/j.canlet.2008.06.014)
26. Jensen KB, Collins CA, Nascimento E, Tan DW, Frye M, Itami S & Watt FM 2009 Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell 4 427-439. (doi:10.1016/j.stem.2009.04.014)
27. Johansson M, Oudin A, Tiemann K, Bernard A, Golebiewska A, Keunen O, Fack F, Stieber D,Wang B, Hedman H et al. 2013 The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro-Oncology 15 1200-1211. (doi:10.1093/neuonc/not054)
28. Kao S, Jaiswal RK, Kolch W & Landreth GE 2001 Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. Journal of Biological Chemistry 276 18169-18177. (doi:10.1074/jbc. M008870200)
29. Karlsson T, Mark EB, Henriksson R & Hedman H 2008 Redistribution of LRIG proteins in psoriasis. Journal of Investigative Dermatology 128 1192-1195. (doi:10.1038/sj.jid.5701175)
30. Krig SR, Frietze S, Simion C,Miller JK, Fry WH, Rafidi H, Kotelawala L, Qi L, Griffith OL, Gray JW et al. 2011 Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERapositive breast cancer. Molecular Cancer Research 9 1406-1417. (doi:10.1158/1541-7786.MCR-11-0227)
31. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL III & Sweeney C 2004 The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. Journal of Biological Chemistry 279 47050-47056. (doi:10.1074/jbc.M409703200)
32. Ledda F, Bieraugel O, Fard SS, Vilar M & Paratcha G 2008 Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. Journal of Neuroscience 28 39-49. (doi:10.1523/JNEUROSCI.2196-07.2008)
33. Lee JM, Kim B, Lee SB, Jeong Y, Oh YM, Song YJ, Jung S, Choi J, Lee S, Cheong KH et al. 2014 Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody. Oncogene 33 34-43. (doi:10.1038/onc.2012.551)
34. Li F, Ye ZQ, Guo DS & Yang WM 2011 Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vectormediated transfer of LRIG1. Oncology Reports 26 439-446. (doi:10.3892/or.2011.1304)
35. Lindquist D, Nasman A, Tarjan M, Henriksson R, Tot T, Dalianis T & Hedman H 2014 Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer. British Journal of Cancer 110 1793-1800. (doi:10.1038/bjc.2014.87)
36. Lu L, Teixeira VH, Yuan Z, Graham TA, Endesfelder D, Kolluri K, Al-Juffali N, Hamilton N, Nicholson AG, Falzon M et al. 2013 LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development. Journal of Pathology 229 608-620. (doi:10.1002/path.4148)
37. Luetteke NC, Phillips HK, Qiu TH, Copeland NG, Earp HS, Jenkins NA & Lee DC 1994 The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes and Development 8 399-413. (doi:10.1101/gad.8.4.399)
38. Mao F, Wang B, Xiao Q, Xi G, Sun W, Zhang H, Ye F, Wan F, Guo D, Lei T et al. 2013 A role for LRIG1 in the regulation of malignant glioma aggressiveness. International Journal of Oncology 42 1081-1087.
39. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Carraway KL III & Sweeney C 2008 Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Research 68 8286-8294. (doi:10.1158/0008-5472.CAN-07-6316)
40. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM et al. 2003 Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22 2361-2373. (doi:10.1038/sj.onc.1206344)
41. Moser AR, Pitot HC & Dove WF 1990 A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247 322-324. (doi:10.1126/science.2296722)
42. Muller S, Lindquist D, Kanter L, Flores-Staino C, Henriksson R, Hedman H & Andersson S 2013 Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma. International Journal of Oncology 42 247-252. (doi:10.3892/ijo.2012.1702)
43. NagataM, Nakamura T, Sotozono C, Inatomi T, Yokoi N& Kinoshita S 2014 LRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasia. PLoS ONE 9 e93164. (doi:10.1371/journal.pone.0093164)
44. Nakamura T, Hamuro J, Takaishi M, Simmons S, Maruyama K, Zaffalon A, Bentley AJ, Kawasaki S, Nagata-Takaoka M, Fullwood NJ et al. 2014 LRIG1 inhibits STAT3-dependent inflammation to maintain corneal homeostasis. Journal of Clinical Investigation 124 385-397. (doi:10.1172/JCI71488)
45. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R & Hedman H 2001 Cloning, characterization, and expression of human LIG1. Biochemical and Biophysical Research Communications 284 1155-1161. (doi:10.1006/bbrc.2001.5092)
46. Oh YM, Lee SB, Choi J, Suh HY, Shim S, Song YJ, Kim B, Lee JM, Oh SJ, Jeong Y et al. 2014 USP8 modulates ubiquitination of LRIG1 for Met degradation. Scientific Reports 4 4980. (doi:10.1038/srep04980)
47. Page ME, Lombard P, Ng F, Gottgens B & Jensen KB 2013 The epidermis comprises autonomous compartments maintained by distinct stem cell populations. Cell Stem Cell 13 471-482. (doi:10.1016/j.stem.2013.07.010)
48. Pang J, Zhang S, Yang P, Hawkins-Lee B, Zhong J, Zhang Y, Ochoa B, Agundez JA, Voelckel MA, Fisher RB et al. 2010 Loss-of-function mutations in HPSE2 cause the autosomal recessive urofacial syndrome. American Journal of Human Genetics 86 957-962. (doi:10.1016/j.ajhg.2010.04.016)
49. Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY & ParkM2001 Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Molecular Cell 8 995-1004. (doi:10.1016/S1097-2765(01)00378-1)
50. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE et al. 2012 The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149 146-158. (doi:10.1016/j.cell.2012.02.042)
51. Powell AE, Vlacich G, Zhao ZY, McKinley ET, Washington MK, Manning HC & Coffey RJ 2014 Inducible loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis. American Journal of Physiology. Gastrointestinal and Liver Physiology 307 G16-G23. (doi:10.1152/ajpgi. 00358.2013)
52. Qi XC, Xie DJ, Yan QF, Wang YR, Zhu YX, Qian C & Yang SX 2013 LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2. Biochemical and Biophysical Research Communications 437 565-572. (doi:10.1016/j.bbrc.2013.06.116)
53. Qian X, Karpova T, Sheppard AM, McNally J & Lowy DR 2004 E-cadherinmediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO Journal 23 1739-1748. (doi:10.1038/sj.emboj.7600136)
54. Rafidi H, Mercado F III, Astudillo M, Fry WH, Saldana M, Carraway KL III & Sweeney C 2013 Leucine-rich repeat and immunoglobulin domaincontaining protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3). Journal of Biological Chemistry 288 21593-21605. (doi:10.1074/jbc.M113.486050)
55. Reifenberger G, Ichimura K, Reifenberger J, Elkahloun AG, Meltzer PS & Collins VP 1996 Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Research 56 5141-5145.
56. Reva B, Antipin Y & Sander C 2011 Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Research 39 e118. (doi:10.1093/nar/gkr407)
57. Roberts NA, Woolf AS, Stuart HM, Thuret R, McKenzie EA, NewmanWG & Hilton EN 2014 Heparanase 2, mutated in urofacial syndrome, mediates peripheral neural development in Xenopus. Human Molecular Genetics 23 4302-4314. (doi:10.1093/hmg/ddu147)
58. Rondahl V, Holmlund C, Karlsson T, Wang B, Faraz M, Henriksson R & Hedman H 2013 Lrig2-deficient mice are protected against PDGFBinduced glioma. PLoS ONE 8 e73635. (doi:10.1371/journal.pone. 0073635)
59. Rouam S, Moreau T & Broet P 2010 Identifying common prognostic factors in genomic cancer studies: a novel index for censored outcomes. BMC Bioinformatics 11 150. (doi:10.1186/1471-2105-11-150)
60. Sethi S, Ali S, Sethi S & Sarkar FH 2014 MicroRNAs in personalized cancer therapy. Clinical Genetics 86 68-73. (doi:10.1111/cge.12362)
61. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KL III & Sweeney C 2007 LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Molecular and Cellular Biology 27 1934-1946. (doi:10.1128/MCB.00757-06)
62. Sheu JJ, Lee CC, Hua CH, Li CI, Lai MT, Lee SC, Cheng J, Chen CM, Chan C, Chao SC et al. 2014 LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling. Oncogene 33 1375-1384. (doi:10.1038/onc.2013.98)
63. Siegelin MD & Borczuk AC 2014 Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory Investigation 94 129-137. (doi:10.1038/labinvest.2013.147)
64. Stuart HM, Roberts NA, Burgu B, Daly SB, Urquhart JE, Bhaskar S, Dickerson JE, Mermerkaya M, Silay MS, Lewis MA et al. 2013 LRIG2 mutations cause urofacial syndrome. American Journal of Human Genetics 92 259-264. (doi:10.1016/j.ajhg.2012.12.002)
65. Stutz MA, Shattuck DL, Laederich MB, Carraway KL III & Sweeney C 2008 LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 27 5741-5752. (doi:10.1038/onc.2008.185)
66. Suzuki Y, Sato N, Tohyama M, Wanaka A & Takagi T 1996 cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains. Journal of Biological Chemistry 271 22522-22527. (doi:10.1074/jbc.271.37.22522)
67. Suzuki Y, Miura H, Tanemura A, Kobayashi K, Kondoh G, Sano S, Ozawa K, Inui S, Nakata A, Takagi T et al. 2002 Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Letters 521 67-71. (doi:10.1016/S0014-5793(02)02824-7)
68. Tanemura A, Nagasawa T, Inui S & Itami S 2005 LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatologic Surgery 31 423-430. (doi:10.1097/00042728-200504000-00008)
69. ThomassonM,Wang B, Hammarsten P, Dahlman A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R et al. 2011 LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. International Journal of Cancer 128 2843-2852. (doi:10.1002/ijc.25820)
70. Thomasson M, Hedman H, Ljungberg B & Henriksson R 2012 Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma. BMC Research Notes 5 216. (doi:10.1186/ 1756-0500-5-216)
71. Thompson PA, Ljuslinder I, Tsavachidis S, Brewster A, Sahin A, Hedman H, Henriksson R, Bondy ML &Melin BS 2014 Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer. Cancer Research 74 2928-2935. (doi:10.1158/0008-5472.CAN-13-2112)
72. Wang B, Han L, Chen R, Cai M, Han F, Lei T & Guo D 2009 Down regulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biology & Therapy 8 1018-1023. (doi:10.4161/cbt.8.11.8375)
73. Wang X, Xiao Q, Xing X, Tian C, Zhang H, Ye F, Wan F,Wang B, Guo D & Lei T 2012 LRIG1 enhances cisplatin sensitivity of glioma cell lines. Oncology Research 20 205-211. (doi:10.3727/096504013X13589503482770)
74. Wang Y, Poulin EJ & Coffey RJ 2013 LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. British Journal of Cancer 108 1765-1770. (doi:10.1038/bjc.2013.138)
75. Wang G, WuJ &Song H 2014 LRIG2 expression and prognosis in non-small cell lung cancer. Oncology Letters 8 667-672. (doi:10.3892/ol.2014. 2157)
76. Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, Itami S, van de Wetering M, Poulsom R, Wright NA, Trotter MW et al. 2012 Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nature Cell Biology 14 401-408. (doi:10.1038/ncb2464)
77. Xie R, Yang H, Xiao Q, Mao F, Zhang S, Ye F, Wan F,Wang B, Lei T & Guo D 2013 Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation. Oncology Reports 29 177-184. (doi:10.3892/or.2012.2102)
78. Ye F, Gao Q, Xu T, Zeng L, Ou Y, Mao F, Wang H, He Y, Wang B, Yang Z et al. 2009 Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. Journal of Neuro-Oncology 94 183-194. (doi:10.1007/s11060-009-9836-1)
79. Yi W, Holmlund C, Nilsson J, Inui S, Lei T, Itami S, Henriksson R & Hedman H 2011 Paracrine regulation of growth factor signaling by shed leucinerich repeats and immunoglobulin-like domains 1. Experimental Cell Research 317 504-512. (doi:10.1016/j.yexcr.2010.11.005)
80. Zhao H, Tanegashima K, Ro H & Dawid IB 2008 Lrig3 regulates neural crest formation in Xenopus by modulating Fgf and Wnt signaling pathways. Development 135 1283-1293. (doi:10.1242/dev.015073)
81. Zhou Y, Luoh SM, Zhang Y, Watanabe C, Wu TD, Ostland M, Wood WI & Zhang Z 2003 Genome-wide identification of chromosomal regions of increased tumor expression by transcriptome analysis. Cancer Research 63 5781-5784.